|
Garcia-Torralba E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, Blaya Boluda N, Lloret Gil M, Aller A, de la Morena Barrio P, Garcia Garre E, Martinez Diaz F, Garcia Molina F, Chaves Benito A, Garcia-Martinez E, Ayala de la Pena F. Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes. Breast Cancer Res Treat. 2024 Jun;205(3):475-485. doi: 10.1007/s10549-024-07286-x. Epub 2024 Mar 7. PubMed PMID: 38453782; PubMed Central PMCID: PMC11101577.
AÑO: 2024; IF: 3.0
|
38453782
|
Martinez-Janez N, Ezquerra MB, Manso Sanchez LM, Carrasco FH, Torres AA, Morales S, Ortega PT, Gil VLO, Sampedro T, Conejero RA, Calvo-Martinez L, Galve-Calvo E, Lopez R, de la Pena FA, Lopez-Tarruella S, de Araguiz BAHF, Ruiz LB, Cardenas TM, Chacon JI, Anton FM. First-line therapy with palbociclib in patients with advanced HR+/HER2- breast cancer: The real-life study PALBOSPAIN. Breast Cancer Res Treat. 2024 Jul;206(2):317-328. doi: 10.1007/s10549-024-07287-w. Epub 2024 Apr 1. PubMed PMID: 38561577; PubMed Central PMCID: PMC11182794.
AÑO: 2024; IF: 3.0
|
|
Sanchez Canovas M, Garcia Torralba E, Blaya Boluda N, Sanchez Saura A, Puche Palao G, Sanchez Fuentes A, Martinez Montesinos L, Poveda Ganga C, Garcia Tomas L, Bayona Jimenez J, Cos Zapata A, Munoz Jurado CM, Pina Mingorance I, Caravaca Hernandez MA, Vicente Garcia V, Ayala de la Pena F. Thrombosis and infections associated with PICC in onco-hematological patients, what is their relevance? Clin Transl Oncol. 2024 Dec;26(12):3226-3235. doi: 10.1007/s12094-024-03548-8. Epub 2024 Jun 12. PubMed PMID: 38865035.
AÑO: 2024; IF: 2.8
|
|
Rodenas MC, Penas-Martinez J, Pardo-Sanchez I, Zaragoza-Huesca D, Ortega-Sabater C, Pena-Garcia J, Espin S, Ricote G, Montenegro S, Ayala-De La Pena F, Luengo-Gil G, Nieto A, Garcia-Molina F, Vicente V, Bernardi F, Lozano ML, Mulero V, Perez-Sanchez H, Carmona-Bayonas A, Martinez-Martinez I. Venetoclax is a potent hepsin inhibitor that reduces the metastatic and prothrombotic phenotypes of hepsin-expressing colorectal cancer cells. Front Mol Biosci. 2023 May 19;10:1182925. doi: 10.3389/fmolb.2023.1182925. eCollection 2023. PubMed PMID: 37275957; PubMed Central PMCID: PMC10235687.
AÑO: 2023; IF: 3.9
|
|
Vera R, Juan-Vidal O, Safont-Aguilera MJ, de la Pena FA, Del Alba AG. Sex differences in the diagnosis, treatment and prognosis of cancer: the rationale for an individualised approach. Clin Transl Oncol. 2023 Jul;25(7):2069-2076. doi: 10.1007/s12094-023-03112-w. Epub 2023 Feb 18. PubMed PMID: 36802013; PubMed Central PMCID: PMC10250517.
AÑO: 2023; IF: 2.8
|